Activity Overview
Research revealing that overexpression of TL1A drives key pathological pathways in inflammatory bowel disease (IBD) has accelerated the development of biologic therapies aimed at inhibiting this ligand. Early studies of investigational anti-TL1A agents—including tulisokibart, afimkibart, and duvakitug—demonstrate encouraging outcomes in patients with moderate to severe IBD, showing improvements in symptoms and reductions in chronic intestinal inflammation and fibrosis. In this fast-moving area, education tailored to gastroenterology-focused clinicians who are navigating an increasingly dynamic IBD treatment landscape is needed. This activity explores emerging evidence and potential clinical applications of TL1A inhibitors. Through case-based discussions and interactive polling, participants will gain practical, up-to-date strategies to enhance IBD management and remain at the forefront of therapeutic innovation.
This educational activity is an archive of the live virtual symposium held on January 23, 2026.
Target Audience
This program is directed towards gastroenterologists, nurse practitioners, physician assistants, internists, nurses, and other health care practitioners who manage patients with IBD.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Summarize the limitations of currently approved advanced targeted drugs in achieving STRIDE II goals for patients with UC or CD
- Describe the role TL1A plays in the inflammatory pathophysiology of UC and CD
- Explain the mechanism of action of TL1A inhibitors in the management of UC and CD
- Evaluate clinical trial efficacy and safety data for anti-TL1A agents in the management of patients with UC or CD
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here